Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STELA biomarker-guided de-escalation study in advanced clear-cell renal cell carcinoma
2026-525749-54-00Phase 2Withdrawn
- Sponsor
- Institute of Oncology Ljubljana
- Start
- Oct 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in clear cell renal cell carcinoma (ccRCC) comparing Pembrolizumab + lenvatinib strategy with Nivolumab + cabozantinib strategy (2 arms). Primary endpoint: 12-month progression-free survival. Planned start Oct 2026; status: withdrawn.
02
Drugs
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2026-525749-54-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525749-54-00.